Scarica l'app Stockscreener
2.86
4.34%
-0.1299
Dopo l'orario di chiusura:
2.86
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire Inc.
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
Rodman & Renshaw sets PolyPid stock at Buy with $13 target - MSN
PolyPid Regains Nasdaq Compliance with Private Placement Boost - TipRanks
Surgical Site Infections Pipeline 2024: Key Companies, MOA, - openPR
Critical Survey: InfuSystem (NYSE:INFU) vs. PolyPid (NASDAQ:PYPD) - Defense World
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress - Investing.com India
PolyPid Ltd. announced that it expects to receive $14.470133 million in funding - Marketscreener.com
FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Price Target Lowered to $11.00 at HC Wainwright - Defense World
PolyPid Advances Phase 3 Trial and Secures Financing - TipRanks
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright - Investing.com Australia
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright By Investing.com - Investing.com South Africa
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - The Manila Times
PolyPid's Surgical Infection Drug Trial Advances with $14.5M Funding Boost; Phase 3 Results Due Q2 2025 - StockTitan
FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter
PolyPid announces research, development collaboration with ImmunoGenesis - Yahoo Finance
PolyPid enters R&D pact with ImmunoGenesis By Investing.com - Investing.com South Africa
PolyPid stock hits 52-week low at $2.81 amid market challenges - Investing.com
PolyPid enters R&D pact with ImmunoGenesis - Investing.com India
PolyPid Collaborates with ImmunoGenesis to Boost Cancer Immunotherapy - TipRanks
PolyPid Announces Research and Development Collaboration - GlobeNewswire
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Yahoo Finance
PolyPid Ltd. Announces Research and Development Collaboration with ImmunoGenesis, Inc. Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Marketscreener.com
PolyPid stock touches 52-week low at $2.93 amid market challenges - Investing.com Nigeria
PolyPid Faces Nasdaq Non-Compliance Challenge - TipRanks
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - GlobeNewswire
PolyPid Faces Nasdaq Non-Compliance, Pivotal Trial Results Due December | PYPD Stock News - StockTitan
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):